Georgia Colleluori1,2, Lina Aguirre3, Nicola Napoli4, Clifford Qualls5, Dennis T Villareal1,2, Reina Armamento-Villareal1,2. 1. Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston 77030, TX, USA. 2. Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, , Houston 77030, TX, USA. 3. New Mexico VA Health Care System, Albuquerque, NM 87108, USA. 4. Department of Endocrinology and Diabetes, Campus Biomedico University, Via Alvaro del Portillo Rome, Italy. 5. Division of Mathematics and Statistics, University of New Mexico School of Medicine, Albuquerque, NM 87108, USA.
Abstract
CONTEXT: Male hypogonadism is associated with low bone mineral density (BMD) and increased fragility fracture risk. Patients with type 2 diabetes (T2D) have relatively higher BMD, but greater fracture risk. OBJECTIVE: Evaluate the skeletal response to testosterone therapy in hypogonadal men with T2D compared with hypogonadal men without T2D. METHODS: Single arm, open-label clinical trial (NCT01378299) involving 105 men (40-74 years old), with average morning testosterone <300 ng/dL. Subjects were injected intramuscularly with testosterone cypionate (200 mg) every 2 weeks for 18 months. Testosterone and estradiol were assessed by liquid chromatography/mass spectrometry; serum C-terminal telopeptide of type I collagen (CTX), osteocalcin and sclerostin by enzyme-linked immunosorbent assay; glycated hemoglobin (HbA1c) by high-performance liquid chromatography, areal BMD (aBMD) and body composition by dual-energy x-ray absorptiometry; tibial volumetric BMD (vBMD) and bone geometry by peripheral quantitative computed tomography. RESULTS: Among our population of hypogonadal men, 49 had T2D and 56 were non-T2D. After 18 months of testosterone therapy, there were no differences in circulating testosterone and estradiol between the groups. Hypogonadal men with T2D had increased osteocalcin, reflecting increased osteoblast activity, compared with non-T2D men (P < .01). T2D men increased lumbar spine aBMD (P < .05), total area at 38% tibia (P < .01) and periosteal and endosteal circumferences at the same site (P < .01 for both). T2D men had reduced tibial vBMD (P < .01), but preserved bone mineral content (P = .01). Changes in HbA1c or body composition were similar between the 2 groups. CONCLUSION: Testosterone therapy results in greater improvements in the skeletal health of hypogonadal men with T2D than their nondiabetic counterparts. Published by Oxford University Press on behalf of the Endocrine Society 2021.
CONTEXT: Male hypogonadism is associated with low bone mineral density (BMD) and increased fragility fracture risk. Patients with type 2 diabetes (T2D) have relatively higher BMD, but greater fracture risk. OBJECTIVE: Evaluate the skeletal response to testosterone therapy in hypogonadal men with T2D compared with hypogonadal men without T2D. METHODS: Single arm, open-label clinical trial (NCT01378299) involving 105 men (40-74 years old), with average morning testosterone <300 ng/dL. Subjects were injected intramuscularly with testosterone cypionate (200 mg) every 2 weeks for 18 months. Testosterone and estradiol were assessed by liquid chromatography/mass spectrometry; serum C-terminal telopeptide of type I collagen (CTX), osteocalcin and sclerostin by enzyme-linked immunosorbent assay; glycated hemoglobin (HbA1c) by high-performance liquid chromatography, areal BMD (aBMD) and body composition by dual-energy x-ray absorptiometry; tibial volumetric BMD (vBMD) and bone geometry by peripheral quantitative computed tomography. RESULTS: Among our population of hypogonadal men, 49 had T2D and 56 were non-T2D. After 18 months of testosterone therapy, there were no differences in circulating testosterone and estradiol between the groups. Hypogonadal men with T2D had increased osteocalcin, reflecting increased osteoblast activity, compared with non-T2D men (P < .01). T2D men increased lumbar spine aBMD (P < .05), total area at 38% tibia (P < .01) and periosteal and endosteal circumferences at the same site (P < .01 for both). T2D men had reduced tibial vBMD (P < .01), but preserved bone mineral content (P = .01). Changes in HbA1c or body composition were similar between the 2 groups. CONCLUSION: Testosterone therapy results in greater improvements in the skeletal health of hypogonadal men with T2D than their nondiabetic counterparts. Published by Oxford University Press on behalf of the Endocrine Society 2021.
Entities:
Keywords:
Type 2 diabetes; bone geometry; bone mineral density; hypogonadism; testosterone
Authors: Georgia Colleluori; Lina Aguirre; Richard Dorin; David Robbins; Dean Blevins; Yoann Barnouin; Rui Chen; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal Journal: Bone Date: 2017-03-16 Impact factor: 4.398
Authors: Franck Oury; Grzegorz Sumara; Olga Sumara; Mathieu Ferron; Haixin Chang; Charles E Smith; Louis Hermo; Susan Suarez; Bryan L Roth; Patricia Ducy; Gerard Karsenty Journal: Cell Date: 2011-02-17 Impact factor: 41.582
Authors: J Verhaeghe; E van Herck; W J Visser; A M Suiker; M Thomasset; T A Einhorn; E Faierman; R Bouillon Journal: Diabetes Date: 1990-04 Impact factor: 9.461
Authors: Moira A Petit; Misti L Paudel; Brent C Taylor; Julie M Hughes; Elsa S Strotmeyer; Ann V Schwartz; Jane A Cauley; Joseph M Zmuda; Andrew R Hoffman; Kristine E Ensrud Journal: J Bone Miner Res Date: 2010-02 Impact factor: 6.741
Authors: G Corona; W Vena; A Pizzocaro; V A Giagulli; D Francomano; G Rastrelli; G Mazziotti; A Aversa; A M Isidori; R Pivonello; L Vignozzi; E Mannucci; M Maggi; A Ferlin Journal: J Endocrinol Invest Date: 2022-01-18 Impact factor: 4.256